S4, commonly known as Andarine, is another selective androgen receptor modulator (SARM) that was initially researched for its potential in treating conditions like muscle wasting, osteoporosis, and benign prostatic hyperplasia (enlarged prostate).

Like other SARMs, Andarine was developed to selectively bind to androgen receptors in the body, influencing them in a way that promotes muscle growth and bone density while potentially minimizing some of the side effects associated with traditional anabolic steroids.

Early research on Andarine suggested that it had an affinity for androgen receptors in muscle and bone tissues, leading to anabolic effects without causing the androgenic side effects often seen with anabolic steroids, such as prostate enlargement or excessive hair growth.

However, as with many SARMs, the research on Andarine is limited and largely based on animal studies or small-scale human trials. The safety profile, long-term effects, and potential risks associated with its use in humans are not well understood.

Furthermore, there have been reports of vision-related side effects associated with Andarine. Some users have experienced issues with vision, particularly a yellow tint or difficulty adjusting to low light. These side effects have raised concerns about the safety of Andarine.

Due to the lack of comprehensive human trials, potential side effects, and safety concerns, it’s crucial to approach the use of Andarine or any similar compound with caution. Consulting with a healthcare professional before considering its use is essential to understand the potential risks and weigh them against any perceived benefits.